PACLITAXEL, FLUOROURACIL, DOCETAXEL, EXEMESTANE, DOXORUBICIN, CYCLOPHOSPHAMIDE, EPIRUBICIN, LETROZOLE, TAMOXIFEN, ANASTROZOLE
GEICAM/2011-03_S1007
Phase 3 small_molecule active
Quick answer
PACLITAXEL, FLUOROURACIL, DOCETAXEL, EXEMESTANE, DOXORUBICIN, CYCLOPHOSPHAMIDE, EPIRUBICIN, LETROZOLE, TAMOXIFEN, ANASTROZOLE for patients with node positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX® is a Phase 3 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cancer Prevention Pharma (Ireland) Limited
- Indication
- patients with node positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX®
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active